Renovaro Inc's fundamentals are relatively weak, Its valuation is considered fairly valued, Institutional ownership is very high.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Renovaro Inc's Score
Industry at a Glance
Industry Ranking
259 / 505
Overall Ranking
431 / 4713
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Renovaro Inc Highlights
StrengthsRisks
Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Undervalued
The company’s latest PE is -5.82, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 65.41M shares, increasing 6.49% quarter-over-quarter.
Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Ticker SymbolRENB
CompanyRenovaro Inc
CEOWeinstein (David)
Website
FAQs
What is the current price of Renovaro Inc (RENB)?
The current price of Renovaro Inc (RENB) is 1.420.
What is the symbol of Renovaro Inc?
The ticker symbol of Renovaro Inc is RENB.
What is the 52-week high of Renovaro Inc?
The 52-week high of Renovaro Inc is 21.000.
What is the 52-week low of Renovaro Inc?
The 52-week low of Renovaro Inc is 1.130.
What is the market capitalization of Renovaro Inc?
The market capitalization of Renovaro Inc is 251.90M.
What is the net income of Renovaro Inc?
The net income of Renovaro Inc is -178.01M.
Is Renovaro Inc (RENB) currently rated as Buy, Hold, or Sell?
According to analysts, Renovaro Inc (RENB) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of Renovaro Inc (RENB)?
The Earnings Per Share (EPS TTM) of Renovaro Inc (RENB) is -0.244.